The essential rule
The FDA prescribing information for both semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro) is clear: these medications should be discontinued before a planned pregnancy. Neither drug is approved for use during pregnancy, and animal studies have shown adverse fetal outcomes at high doses.
This guide covers the practical questions: how far in advance to stop, what happens to fertility, and how to plan the transition.
Recommended washout periods
The washout period is determined by the drug's half-life — the time it takes for the drug concentration in your body to drop by half. Generally, 5 half-lives clears roughly 97% of the drug from your system.
Semaglutide (Ozempic, Wegovy): Half-life is approximately 7 days. The FDA recommends discontinuing semaglutide at least 2 months before a planned pregnancy. This provides approximately 8–9 half-lives of clearance.
Tirzepatide (Zepbound, Mounjaro): Half-life is approximately 5 days. The FDA recommends discontinuing tirzepatide at least 1 month before a planned pregnancy. This provides approximately 6 half-lives of clearance.
Oral semaglutide (Rybelsus): Same active ingredient as injectable semaglutide, same 2-month recommendation.
These are minimum recommendations. Some reproductive endocrinologists advise a full 3-month washout for semaglutide to provide extra margin and align with the typical pre-conception optimization window.
Why the washout matters
The concern isn't about acute toxicity — it's about potential developmental effects during the earliest stages of pregnancy, when many women don't yet know they're pregnant. GLP-1 receptors are expressed in embryonic tissues, and animal studies (at doses much higher than therapeutic human doses) showed increased rates of fetal malformations and pregnancy loss.
No adequate human studies exist because it would be unethical to randomize pregnant women to a medication with known animal risks. The precautionary principle applies: clear the drug before conception.
GLP-1s and fertility
There's an important nuance here that many patients miss: GLP-1 medications can actually increase fertility, sometimes unexpectedly.
PCOS and ovulation. Many women with obesity have polycystic ovary syndrome (PCOS), which disrupts ovulation. Weight loss — even 5–10% of body weight — can restore regular ovulatory cycles. Women on GLP-1s who haven't been ovulating regularly may start ovulating again as they lose weight, sometimes within the first few months of treatment.
The "Ozempic baby" phenomenon. Reports of unplanned pregnancies on GLP-1s have become common enough to generate media coverage. The mechanism is likely weight-loss-mediated fertility restoration rather than a direct drug effect, but the practical implication is the same: if you're sexually active and not planning pregnancy, use reliable contraception while on a GLP-1.
Oral contraceptive absorption. GLP-1 medications slow gastric emptying, which can theoretically affect the absorption of oral contraceptives. The clinical significance of this is debated, but some prescribers recommend backup contraception (condoms, IUD) during GLP-1 treatment if pregnancy prevention is important. This is especially relevant during dose titration when GI effects are most pronounced.
Planning the transition off
Stopping a GLP-1 before pregnancy requires a thoughtful transition plan to minimize weight regain:
Work with your prescriber. Don't stop abruptly without a plan. Discuss timing, transition strategies, and alternative weight maintenance approaches.
Taper if possible. Some prescribers recommend stepping down to a lower dose for 4–6 weeks before stopping completely, rather than going from maintenance dose to zero. This may ease the transition.
Establish habits before stopping. The 2–3 months before your planned washout are critical for solidifying the eating and exercise habits that will sustain your weight without medication support. Prioritize protein intake, consistent meal timing, and a regular exercise routine.
Expect appetite return. When the GLP-1 clears your system, appetite and food noise will return to some degree. This is normal and expected. Having a structured nutrition plan in place before this happens makes a significant difference.
Monitor weight, don't panic. Some weight regain after stopping is common and often includes water weight and glycogen restoration. A 3–5 lb increase in the first few weeks doesn't necessarily mean you're regaining fat.
What about men?
There is no established evidence that GLP-1 medications affect male fertility or sperm quality. The FDA does not recommend a washout period for male partners planning conception. However, limited data exists, and some reproductive specialists may suggest a cautious approach.
If you're a male patient concerned about fertility, discuss with your prescriber. GLP-1-mediated weight loss can actually improve testosterone levels and sperm parameters in men with obesity.
After pregnancy
Most women can resume GLP-1 therapy after delivery, but timing depends on breastfeeding plans:
If not breastfeeding: GLP-1 therapy can typically resume after postpartum recovery (6–8 weeks post-delivery), pending provider approval.
If breastfeeding: Semaglutide and tirzepatide are not recommended during breastfeeding due to insufficient data. The drugs are large peptides that could theoretically pass into breast milk. Most providers recommend completing breastfeeding before restarting.
The bottom line
GLP-1 medications require advance planning around pregnancy. The washout is non-negotiable — 2 months for semaglutide, 1 month for tirzepatide, minimum. The surprising part for many patients is that the medication itself may improve fertility through weight loss, making reliable contraception essential if you're not actively trying to conceive.
Plan the transition with your prescriber, build sustainable habits during the washout window, and don't stop your contraception until you're actually ready to conceive. This isn't a case where the answer is complicated — it just requires deliberate timing.